Ooooooooh, so now this makes sense as to 'why' out of the blue, Neil Young was speaking out against Rogan and giving Spotify an ultimatum
Apparently, Young sold half of his catalog to a song management company last year, who they then merged with Blackstone. And Blackstone appointed ex-Pfizer CEO to be their Senior Advisor
Now follow the bouncing ball, folks....
SOURCE
It is likely that Jeffrey B Kindler “advised” their musicians to take a stand against Spotify for hosting a podcast that has been critical of COVID-19 vaccines, especially since Rogan reaches 11 million people per episode. That could significantly impact big pharma’s pockets.
Apparently, Young sold half of his catalog to a song management company last year, who they then merged with Blackstone. And Blackstone appointed ex-Pfizer CEO to be their Senior Advisor
Now follow the bouncing ball, folks....
Quote:Internet sleuths were absolutely shocked by this former freedom-loving hippies stance on freedom of speech and alternative medicine that they did some digging and they found that Neil Young is financially tied to Pfizer. The big pharma giant owns him and his music!
On January 6, 2021, Neil Young sold half of his catalogue to Merck Mercuriadis’ Hipgnosis Song Management company. Later that year Hipgnosis merged with Blackstone in a USD$1Bn deal. However, just a month before the merger Blackstone announced that they appointed Pfizer’s former Chairman and CEO Jeffrey B Kindler as the company’s Senior Advisor.
SOURCE
It is likely that Jeffrey B Kindler “advised” their musicians to take a stand against Spotify for hosting a podcast that has been critical of COVID-19 vaccines, especially since Rogan reaches 11 million people per episode. That could significantly impact big pharma’s pockets.
Quote:Although Jeffrey B Kindler no longer serves in Pfizer’s boardroom, it is likely that he still owns a bunch of Pfizer (NYSE:PSE) stock as it has not been reported that the former CEO has sold any of his holdings. Regardless, he’s still also very connected to big pharma considering he is still the CEO of Centrexion Therapeutics.
Centrexion Therapeutics is a privately owned drug company valued at around USD$70bn.